JAMA dermatology最新文献

筛选
英文 中文
Autoinflammatory Syndromes-Recognizing Autoinflammatory Diseases in Dermatology. 自身炎症综合征-识别皮肤病学中的自身炎症性疾病。
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-11 DOI: 10.1001/jamadermatol.2026.4533
Laura Calabrese, Benjamin Kendziora, Lars Einar French
{"title":"Autoinflammatory Syndromes-Recognizing Autoinflammatory Diseases in Dermatology.","authors":"Laura Calabrese, Benjamin Kendziora, Lars Einar French","doi":"10.1001/jamadermatol.2026.4533","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.4533","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diffuse Lip Swelling and Oral Nodules in an Adolescent. 青少年弥漫性唇肿及口腔结节。
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-11 DOI: 10.1001/jamadermatol.2026.4603
Qingying Lan, Hong Hua, Peiru Zhou
{"title":"Diffuse Lip Swelling and Oral Nodules in an Adolescent.","authors":"Qingying Lan, Hong Hua, Peiru Zhou","doi":"10.1001/jamadermatol.2026.4603","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.4603","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Characteristics, Etiologic Associations, and Treatment Outcomes of Pernio. 腹股沟的临床特点、病因关联及治疗结果。
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-11 DOI: 10.1001/jamadermatol.2026.4339
Kaitlin Martins, Zasca-Aisha Ristianto, Sophia Manduca, Camille Scandurro, Mackenzie R Martin, Daniel R Mazori, Avrom S Caplan, Alisa N Femia
{"title":"Clinical Characteristics, Etiologic Associations, and Treatment Outcomes of Pernio.","authors":"Kaitlin Martins, Zasca-Aisha Ristianto, Sophia Manduca, Camille Scandurro, Mackenzie R Martin, Daniel R Mazori, Avrom S Caplan, Alisa N Femia","doi":"10.1001/jamadermatol.2026.4339","DOIUrl":"10.1001/jamadermatol.2026.4339","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756197/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tuberculosis Verrucosa Cutis With Chronic Lymphedema. 疣状皮肤结核伴慢性淋巴水肿。
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-11 DOI: 10.1001/jamadermatol.2026.4569
Bin Peng, Jutamas Kaminsin, Longfei Zhu, Songmei Geng
{"title":"Tuberculosis Verrucosa Cutis With Chronic Lymphedema.","authors":"Bin Peng, Jutamas Kaminsin, Longfei Zhu, Songmei Geng","doi":"10.1001/jamadermatol.2026.4569","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.4569","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence of Cancer in Morphea and Systemic Sclerosis. 睡眠和系统性硬化症的癌症发病率。
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-11 DOI: 10.1001/jamadermatol.2026.4685
Jessica Muha, Maxine Joly-Chevrier, Hacene Nedjar, Florence Julien, Katherine Aw, Anastasiya Muntyanu, Stephanie Ghazal, Sabrina Hundal, Mohamed Osman, Marc Dorais, Elham Rahme, Mohammed Kaouache, Elena Netchiporouk
{"title":"Incidence of Cancer in Morphea and Systemic Sclerosis.","authors":"Jessica Muha, Maxine Joly-Chevrier, Hacene Nedjar, Florence Julien, Katherine Aw, Anastasiya Muntyanu, Stephanie Ghazal, Sabrina Hundal, Mohamed Osman, Marc Dorais, Elham Rahme, Mohammed Kaouache, Elena Netchiporouk","doi":"10.1001/jamadermatol.2026.4685","DOIUrl":"10.1001/jamadermatol.2026.4685","url":null,"abstract":"<p><strong>Importance: </strong>Systemic sclerosis (SSc) is associated with increased risk of cancer, but population-level data on cancer risk in morphea remain limited and conflicting.</p><p><strong>Objective: </strong>To compare the incidence and standardized incidence ratios (SIRs) of overall and site-specific cancers in patients with morphea and SSc compared with the general population, and to identify factors associated with incident cancer.</p><p><strong>Design, setting, and participants: </strong>This is a retrospective, population-based cohort study using linked administrative health databases (1996-2019) from Quebec, Canada, with follow-up through December 31, 2020. Patients were identified using published diagnostic algorithms requiring at least 2 billing claims with relevant International Classification of Diseases, Ninth Revision, and/or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, codes at least 2 months apart, with specialist diagnosis or hospitalization. Data were analyzed from June 2025 to June 2026.</p><p><strong>Exposures: </strong>Diagnosis of morphea or SSc.</p><p><strong>Main outcomes and measures: </strong>Incident cancers were ascertained through linkage to the provincial cancer registry. SIRs were calculated with respect to the general population using Canadian Cancer Registry rates. Cumulative incidence was estimated using Fine-Gray competing risk methods; associated factors were evaluated with multivariable Cox regression.</p><p><strong>Results: </strong>There were 6181 patients with morphea (median [IQR] age at diagnosis, 56 [40-68] years; 4605 female [74.50%]; 71 221.53 person-years of follow-up) and 8133 patients with SSc (median [IQR] age at diagnosis, 58 [48-69] years; 6530 female [80.29%]; 71 844.36 person-years of follow-up). During follow-up, 782 patients with morphea (12.65%) and 1104 with SSc (13.57%) developed cancer. Overall cancer incidence was increased in both the morphea (SIR, 1.24; 95% CI, 1.14-1.35) and SSc (SIR, 1.37; 95% CI, 1.27-1.48) cohorts. Solid tumor risk was elevated in both cohorts (morphea SIR, 1.17; 95% CI, 1.06-1.29; SSc SIR, 1.21; 95% CI 1.11-1.32). Hematologic cancer risk was markedly elevated in patients with SSc (SIR, 2.40; 95% CI, 1.92-2.96) but not statistically significant for those with morphea (SIR, 1.34; 95% CI, 0.97-1.81). Female reproductive and breast cancers predominated in the morphea group; lung cancer was most frequent among patients with SSc. Younger patients carried the highest relative risk. Immunosuppressant use was associated with lower cancer risk in patients with morphea (hazard ratio, 0.56; 95% CI, 0.46-0.68) and those with SSc (hazard ratio, 0.63; 95% CI, 0.55-0.70).</p><p><strong>Conclusions and relevance: </strong>This cohort study found that morphea and SSc were associated with increased cancer incidence compared with the general population, with distinct cancer profiles between the 2 conditions. These finding","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking Low Disease Activity in Atopic Dermatitis. 对特应性皮炎低疾病活动性的再思考
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-11 DOI: 10.1001/jamadermatol.2026.4344
Christopher G Bunick
{"title":"Rethinking Low Disease Activity in Atopic Dermatitis.","authors":"Christopher G Bunick","doi":"10.1001/jamadermatol.2026.4344","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.4344","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking Low Disease Activity in Atopic Dermatitis-Reply. 对特应性皮炎低疾病活动性的再思考
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-11 DOI: 10.1001/jamadermatol.2026.4328
Joseph F Merola, Alan D Irvine, Robert Bissonnette
{"title":"Rethinking Low Disease Activity in Atopic Dermatitis-Reply.","authors":"Joseph F Merola, Alan D Irvine, Robert Bissonnette","doi":"10.1001/jamadermatol.2026.4328","DOIUrl":"https://doi.org/10.1001/jamadermatol.2026.4328","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Errors in Figure 2 and the Methods. 图2中的错误和方法。
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-11 DOI: 10.1001/jamadermatol.2026.4997
{"title":"Errors in Figure 2 and the Methods.","authors":"","doi":"10.1001/jamadermatol.2026.4997","DOIUrl":"10.1001/jamadermatol.2026.4997","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of Chronic Hand Eczema in Adults. 成人慢性手湿疹的患病率。
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-11 DOI: 10.1001/jamadermatol.2026.4674
Raj Chovatiya, Sanjeev Balu, Aseel Bin Sawad, Eydna Didriksen Apol, Shannon Schneider, Douglas Maslin, Lysel Brignoli, Perrine Le Calvé, Eric L Simpson
{"title":"Prevalence of Chronic Hand Eczema in Adults.","authors":"Raj Chovatiya, Sanjeev Balu, Aseel Bin Sawad, Eydna Didriksen Apol, Shannon Schneider, Douglas Maslin, Lysel Brignoli, Perrine Le Calvé, Eric L Simpson","doi":"10.1001/jamadermatol.2026.4674","DOIUrl":"10.1001/jamadermatol.2026.4674","url":null,"abstract":"<p><strong>Importance: </strong>The prevalence of chronic hand eczema (CHE) is poorly characterized in the US due to limited epidemiological data and no specific International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) code, underscoring the need to better characterize its burden.</p><p><strong>Objective: </strong>To estimate the prevalence of self-reported health care professional-diagnosed CHE among a quota-based sample of US adults.</p><p><strong>Design, setting, and participants: </strong>This cross-sectional study uses data from the Chronic Hand Eczema Epidemiology, Care, and Knowledge of Real-Life Burden in the US (CHECK-US), an online survey of US adults recruited via actively managed online research panels conducted between March 27 and May 19, 2025. A screening questionnaire identified participants with CHE (hand eczema lasting continuously for ≥3 months or ≥2 flares within the past 12 months). Participants also reported whether they had received a health care professional diagnosis for their CHE. Data were analyzed from May 2025 through February 2026.</p><p><strong>Main outcomes and measures: </strong>Prevalence estimates were calculated for the overall population and stratified by sex, age, employment status, current residence (urban or rural), region, and race.</p><p><strong>Results: </strong>Among 10 636 participants (mean [SD] age, 42.9 [14.3] years; 5355 male [50.3%]), 1019 participants (mean [SD] age, 37.2 [12.5] years; 557 male [54.7%]) self-reported health care professional-diagnosed CHE, yielding a prevalence of 9.6% (95% CI, 9.0%-10.2%) irrespective of disease severity or treatment. Among these, 772 participants (75.8%) reported hand eczema continuously for 3 or more months and 2 or more flare episodes in the past 12 months. Subgroup analyses indicated that CHE was more prevalent among males than females (10.5% [95% CI, 9.7%-11.3%] vs 8.7% [95% CI, 7.8%-9.5%]; P < .001), employed than unemployed participants (10.3% [95% CI, 9.6%-11.1%] vs 7.8% [95% CI, 6.9%-8.6%]; P < .001), urban than rural residents (10.4% [95% CI, 9.7%-11.0%] vs 6.3% [95% CI, 5.2%-7.5%]; P < .001), and males aged 18 to 49 years compared with females in the same age range (18 to 29 years: 14.7%; 95% CI, 13.0%-16.3% vs 12.1%; 95% CI, 9.8%-14.4 %; P = .08; 30 to 39 years: 14.9%; 95% CI, 12.8%-17.0% vs 12.0%; 95% CI, 10.1%-13.9%; P = .05; 40-49 years: 13.6%; 95% CI, 11.5%-15.8% vs 8.2%; 95% CI, 6.5%-10.0%; P < .001).</p><p><strong>Conclusion and relevance: </strong>These findings from a large epidemiological study estimating the prevalence of CHE in US adults suggest that CHE is a common skin disease in the US and emphasize the need for more comprehensive research to accurately quantify the burden of CHE and inform evidence-based prevention and management strategies.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13756196/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis: A Phase 2 Randomized Clinical Trial. 布雷西替尼治疗皮肤结节病的疗效和安全性:一项2期随机临床试验。
IF 10.9 1区 医学
JAMA dermatology Pub Date : 2026-11-10 DOI: 10.1001/jamadermatol.2026.5444
Misha Rosenbach, Bridget E Shields, Margaret Coates, Ogugua Ndili Obi, Anne L Marano, Aaron R Mangold, Oluwakemi Onajin, Anna Haemel, David Fivenson, Daniel A Culver, Marc A Judson, Claire Hannah, Craig Smuda, Samantha Polly, Rashmi Unwala, Logan Harper, Manuel L Ribeiro Neto, W Ennis James, Paras Vakharia, Cuong V Nguyen, Galen Foulke, Mina Al-Awqati, Matthew Helm, Sylvia Hsu, Rohit Gupta, Donna A Culton, Robert Pariser, Jordan Talia, Matthew C Baker, Katharina S Shaw, Brendan Johnson, Matthew D Cascino, Brian Mandell, Nadera Sweiss, Lauren Graham, Joseph Barney, Sotonye Imadojemu, Avrom S Caplan, William Damsky
{"title":"Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis: A Phase 2 Randomized Clinical Trial.","authors":"Misha Rosenbach, Bridget E Shields, Margaret Coates, Ogugua Ndili Obi, Anne L Marano, Aaron R Mangold, Oluwakemi Onajin, Anna Haemel, David Fivenson, Daniel A Culver, Marc A Judson, Claire Hannah, Craig Smuda, Samantha Polly, Rashmi Unwala, Logan Harper, Manuel L Ribeiro Neto, W Ennis James, Paras Vakharia, Cuong V Nguyen, Galen Foulke, Mina Al-Awqati, Matthew Helm, Sylvia Hsu, Rohit Gupta, Donna A Culton, Robert Pariser, Jordan Talia, Matthew C Baker, Katharina S Shaw, Brendan Johnson, Matthew D Cascino, Brian Mandell, Nadera Sweiss, Lauren Graham, Joseph Barney, Sotonye Imadojemu, Avrom S Caplan, William Damsky","doi":"10.1001/jamadermatol.2026.5444","DOIUrl":"10.1001/jamadermatol.2026.5444","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Cutaneous sarcoidosis (CS) is a chronic granulomatous skin disease associated with substantial morbidity and no approved therapies.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate the efficacy and safety of brepocitinib, an oral, selective, tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, in adults with CS.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;BEACON is an ongoing, global, multicenter, randomized, double-blind, placebo-controlled phase 2/3 trial. This prespecified interim analysis evaluated the 16-week, dose-ranging phase 2 portion of the study conducted between April 9, 2025, and July 18, 2025. Adults with biopsy-proven active CS were randomized 3:2:2 to receive brepocitinib, 45 mg; brepocitinib, 15 mg; or placebo once daily.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;The primary efficacy outcome was change from baseline in the Cutaneous Sarcoidosis Activity and Morphology Instrument-Activity (CSAMI-A) score at week 16. Additional outcomes included achievement of Cutaneous Sarcoidosis Activity-Investigator Global Assessment (CSA-IGA) clear or almost clear with a 2 or greater category improvement, CSAMI-A response (≥50% relative improvement), 10-point or greater CSAMI-A score reduction, achievement of a CSAMI-A score less than 5, patient-reported outcomes, and safety.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Thirty-one participants (mean [SD] age, 53.3 [9.6] years; 18 female individuals [58%] and 13 male individuals [42%]) were enrolled. Both brepocitinib doses achieved rapid, significant improvements in CS disease activity: by week 16, CSAMI-A scores improved by 22.3 points in the 45-mg group and 22.2 points in the 15-mg group compared with a 0.7-point improvement with placebo (P &lt; .001). Across increasingly stringent responder-based and cutaneous remission-oriented end points, efficacy consistently favored brepocitinib, 45 mg, supporting a dose-dependent treatment effect. Compared with placebo, brepocitinib, 45 mg, resulted in higher rates of CSA-IGA clear or almost clear disease (69.2% vs 0%; P = .01), CSAMI-A response (76.9% vs 0%; P = .003), ≥10-point CSAMI-A reduction (100% vs 14.3%; P &lt; .001), and achievement of a CSAMI-A score of less than 5 (61.5% vs 0%; P = .005). Clinical benefit extended to difficult to treat phenotypes, including lupus pernio, despite protocol-mandated systemic glucocorticoid discontinuation, and was accompanied by substantial improvements in skin-related quality of life. No deaths or serious adverse events occurred.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;In the phase 2 portion of the BEACON randomized clinical trial, brepocitinib produced rapid, dose-dependent, and clinically meaningful improvements in CS. As the first randomized, placebo-controlled trial to demonstrate efficacy of a targeted therapy in CS, these findings support selective TYK2/JAK1 inhibition as a potentially promising therapeutic strategy for CS and support ongoing phase 3 e","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":10.9,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13752788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149386586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书